Sign up for our daily Newsletter and stay up to date with all the latest news!

Subscribe I am already a subscriber

You are using software which is blocking our advertisements (adblocker).

As we provide the news for free, we are relying on revenues from our banners. So please disable your adblocker and reload the page to continue using this site.

Click here for a guide on disabling your adblocker.

Sign up for our daily Newsletter and stay up to date with all the latest news!

Subscribe I am already a subscriber

US (NV): Tissue culture company files for bankruptcy

Pharmagreen Biotech has voluntarily filed for petitions for relief under chapter 11 of the U.S. Bankruptcy Code in the U.S. Bankruptcy Court for the District of Nevada.

“As we started to execute on our business plan, earlier this year before the spread of COVID-19, we completed financing that carried toxic terms after 6 months. Due to the Pandemic, our ETN process got delayed as Europe shut down for over two months, and these notes became due and as result these lenders are seeking very toxic conversions that would essentially wipe out the company’s valuation. After taking much time to carefully analyze our strategic options, we have decided that a voluntary chapter 11 filing provides the best possible outcome for Pharmagreen,” said Pharmagreen Biotech CEO Peter Wojcik. “We plan to engage all our lenders to settle debts in a way that is fair and beneficial for all parties going forward.”

The Company has filed customary motions with the Bankruptcy Court that will allow, upon Bankruptcy Court approval, the Company’s ability to continue operations in the ordinary course of business, including, among other things, payment of suppliers and vendors and the use of cash collateral. These motions are typical in the Chapter 11 process and the Company anticipates that they will be approved shortly after the commencement of its Chapter 11 case. The Company plans to use the Chapter 11 process to build a comprehensive restructuring plan that will allow the Company to emerge from Chapter 11 with a manageable balance sheet.

“We are working non-stop on expediting the in-court restructuring that will allow us to maintain our operational momentum and uphold the obligations we have to our shareholders,” says Wojcik. “We could not allow these toxic lenders to harm our company any further and the investments made by our loyal shareholders.”

“We feel that we can secure necessary additional funding and, coupled with Pharmagreen Inc.’s ETN asset backed bond scheduled to begin trading on the European markets in the near future, we can successfully exit this process with a more successful future.”

For more information:

Publication date: